SRP8053
IL-35 (mouse): FC (human)
recombinant, expressed in CHO cells
Synonym(s):
Interleukin-35, T-cell immunoglobulin and mucin domain-containing protein 4
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352200
NACRES:
NA.32
Recommended Products
biological source
human
mouse
recombinant
expressed in CHO cells
Assay
≥98% (SDS-PAGE)
form
lyophilized
mol wt
monomer 23 kDa by calculation (IL-12a (p35))
monomer 46 kDa by calculation (Ebi3)
packaging
pkg of 5 μg
technique(s)
activity assay: suitable
impurities
<0.06 EU/μg endotoxin, tested
color
white
shipped in
wet ice
storage temp.
−20°C
Gene Information
mouse ... Ebi3(50498) , Il12a(16159)
General description
Research area: IMMUNO AND CKS. Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs.
Application
IL-35 has been used to study its immunosuppressive effect on acute graft-versus-host disease in a mouse model.Ithas also been used to study its effects on the differentiation of granulocytemacrophage-colony-stimulating factor-producing T helper cells (ThGM). IL-35has been used to study its effects on bleomycin-induced pulmonary fibrosis.
Biochem/physiol Actions
Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells′ ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.IL-35 is produced inresponse to agonists of toll-like receptors 3 and 4 (TLR 3 & 4) and interferon γ (IFN-γ). It is secreted mainly by activated B cells, CD4+ Foxp3+ regulatoryT cells (Tregs), and at a lower concentration by monocytes, smooth muscle cells, and endothelial cells.
Physical form
Lyophilized from 0.2 μm-filtered solution in PBS.
Reconstitution
Reconstitute at 100 μg/mL in sterile PBS.
Other Notes
The mouse IL-35 complex composed of the Ebi3 subunit (aa 23-228) and the IL-12a (p35) subunit (aa 23-215) is fused through a polypeptide linker to the Fc region of human IgG1.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells.
Niedbala W
European Journal of Immunology, 37, 3021-3029 (2007)
Chen Xu et al.
Neurochemical research, 43(7), 1454-1463 (2018-06-20)
IL-35 has been identified as a novel anti-inflammatory cytokine that belongs to the IL-12 cytokine family and has been verified to play a protective role in autoimmune diseases. In this study, we investigated the protective effects of IL-35 on cerebral
Fengqin Lin et al.
Molecular immunology, 164, 28-38 (2023-11-09)
The immune system contributes to the pathophysiology of endometriosis. The role of ThGM cells, which produce granulocyte macrophage-colony-stimulating factor (GM-CSF), in the pathogenesis of endometriosis remains unknown. To analyze the features of ThGM cells in endometriosis, a mouse endometriosis model
The inhibitory cytokine IL-35 contributes to regulatory T-cell function.
Collison LW
Nature, 450, 566-569 (2007)
Jinjung Choi et al.
Clinical reviews in allergy & immunology, 49(3), 327-332 (2015-01-27)
Interleukin 35 (IL-35) is the most recently identified member of the IL-12 family of cytokines and offers the potential to be a target for new therapies for autoimmune, inflammatory, and infectious diseases. Similar to other members of the IL-12 family
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service